Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Director | June 20, 2024 | June 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
C4 Therapeutics, Inc.
Report date June 20, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.05 · Expires 2034-06-19 | Direct | 32,500 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 32,500 · Balance 32,500 F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 20, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 20, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2024 Filed Jun 21, 2024 16:07 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 32,500 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001662579-24-000056 · wk-form4_1719000433.xml · derivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2034-06-19 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 20, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 16:22 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001662579-23-000055 · wk-form4_1686946925.xml · derivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 16:15 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $6.06 | $0.00 |
DisclosureSEC source: 0001209191-22-038862 · doc4.xml · derivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2032-06-21 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| January 04, 2022 Filed Jan 18, 2022 16:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 428 | $31.58 | $13,516.24 |
DisclosureSEC source: 0001209191-22-003504 · doc4.xml · nonDerivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,380 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 4, 2022. Read SEC document |
| December 17, 2021 Filed Dec 17, 2021 16:28 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 755 | $30.25 | $22,838.75 |
DisclosureSEC source: 0001209191-21-070273 · doc4.xml · nonDerivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,952 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on April 15, 2021. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 16:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 755 | $40.11 | $30,283.05 |
DisclosureSEC source: 0001209191-21-065820 · doc4.xml · nonDerivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,707 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on April 15, 2021. Read SEC document |
| October 15, 2021 Filed Oct 15, 2021 16:36 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 755 | $44.94 | $33,929.70 |
DisclosureSEC source: 0001209191-21-060568 · doc4.xml · nonDerivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,462 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on April 15, 2021. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 16:56 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 300 | $44.99 | $13,497.00 |
DisclosureSEC source: 0001209191-21-059530 · doc4.xml · nonDerivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,217 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 4, 2021. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 19:25 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 755 | $49.89 | $37,666.95 |
DisclosureSEC source: 0001209191-21-057117 · doc4.xml · nonDerivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,917 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on April 15, 2021. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 17:01 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 755 | $40.73 | $30,751.15 |
DisclosureSEC source: 0001209191-21-053162 · doc4.xml · nonDerivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,672 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on April 15, 2021. Read SEC document |
| July 16, 2021 Filed Jul 19, 2021 16:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 755 | $37.37 | $28,214.35 |
DisclosureSEC source: 0001209191-21-047169 · doc4.xml · nonDerivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,427 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on April 15, 2021. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 16:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 339 | $39.72 | $13,465.08 |
DisclosureSEC source: 0001209191-21-045808 · doc4.xml · nonDerivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,182 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 2, 2021. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:23 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 755 | $37.19 | $28,078.45 |
DisclosureSEC source: 0001209191-21-042300 · doc4.xml · nonDerivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,843 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on April 15, 2021. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 16:15 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $37.66 | $0.00 |
DisclosureSEC source: 0001209191-21-041425 · doc4.xml · derivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2022 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 21, 2021 Filed May 24, 2021 18:42 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | SaleCommon Stock | 755 | $37.12 | $28,025.60 |
DisclosureSEC source: 0001209191-21-035501 · doc4.xml · nonDerivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,598 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on April 15, 2021. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 16:30 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantCommon Stock | 359 | $37.51 | $13,466.09 |
DisclosureSEC source: 0001209191-21-025663 · doc4.xml · nonDerivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,353 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 5, 2021. Read SEC document |
| October 06, 2020 Filed Oct 6, 2020 21:26 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionSeries B Preferred Stock · Derivative | 23,809 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027692 · doc4.xml · derivative · entry 5 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,823 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. Read SEC document |
| October 06, 2020 Filed Oct 6, 2020 21:26 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionSeries A Preferred Stock · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027692 · doc4.xml · derivative · entry 4 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,856 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. Read SEC document |
| October 06, 2020 Filed Oct 6, 2020 21:26 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | PurchaseCommon Stock | 1,315 | $19.00 | $24,985.00 |
DisclosureSEC source: 0000899243-20-027692 · doc4.xml · nonDerivative · entry 3 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,994 Read SEC document |
| October 06, 2020 Filed Oct 6, 2020 21:26 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionCommon Stock | 2,823 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-027692 · doc4.xml · nonDerivative · entry 2 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. Read SEC document |
| October 06, 2020 Filed Oct 6, 2020 21:26 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | ConversionCommon Stock | 11,856 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-027692 · doc4.xml · nonDerivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:00 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 17,786 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027449 · doc4.xml · derivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,786 Underlying: Common Stock · 17,786 shares Expires 2030-09-30 F1 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) October 1, 2021, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.